Pharma matters

The latest issue of my Cutting Edge of Chemistry report for TR Pharma Matters is now available.

Organic synthesis scheme showcase in this report, we look at a chemoenzymatic approach that shows promise for a more efficient route to synthesize ultra low molecular weight heparins.

Scaffolds on the move – dihydronaphthyridinediones could represent a novel structural class of potent and selective phosphodiesterase PDE7 inhibitors for the treatment of cognitive disorders. Also showcased are antimalarial agents, oncolytic drugs, and drugs to combat HIV.

New molecular mechanisms of action hydroxyacid oxidase 2 (HAOX2, HAO2) inhibitors, integrin alphaMbeta2 (MAC-1) agonists and histone acetyltransferase (HAT) activators, among a range of other compounds, are showcased in this issue.

The starting line – a selection of new molecular entities ready to progress in the R&D arena including pharmacological activity, originator, and chemical structure.

New drugs for old – the search for new drugs is an increasingly costly business. With patents expiring and pipelines drying up it is possible that the pharmaceutical industry is truly at the end of the so-called era of blockbusters. In this article, we look at how the industry is finding ways to reformulate and repurpose old products to new diseases and extracting novel applications for known agents.

The report is available as a PDF here.

Author: bob投注平台

Award-winning freelance science writer, author of Deceived Wisdom. Sharp-shooting photographer and wannabe rockstar.